A178 DISEASE COURSE AND MANAGEMENT OF CHILDREN WITH VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE
Bibliographic record
Abstract
Abstract Background Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed before 6 years of age, has a distinct phenotype with predominantly colonic involvement. However, there are limited studies describing the long-term outcome of children with VEO-IBD. Aims Our primary aim was to determine the long-term outcome in children with VEO-IBD and corticosteroid free clinical remission (CFCR) at one year post diagnosis and at last follow up. The secondary aim was to determine clinical response (CR) and biochemical remission (BR) at the same time points. Methods A retrospective cross-sectional chart review was conducted for all children with VEOIBD diagnosed between 1st January 2013 to 31st December 2022 with a minimum follow up of one year at British Columbia Children’s Hospital (BCCH). Patients were identified from the BCCH pediatric IBD database. Demographic and relevant clinical data including IBD medications and response were collected. Data points at 3 months, 6months, 1 year and then annually until 10 years from diagnosis were collected. Corticosteroid free clinical remission (CFCR) was defined as being off steroids for ≥ 3 months at yearly follow up. Biochemical remission (BR) was defined as fecal calprotectin <250ug/g. Clinical response (CR) was defined as a wPCDAI >17.5-point change or a PUCAI of a 20-point change from baseline. Results 77 patients were identified, with 70 patients reviewed thus far. The mean age at diagnosis was 45.6 (±16.4 months). The median follow-up time was 60 months (interquartile range 36 to 84 months). Of the 38 (54%) patients on biologic therapy, the most common 1st, 2nd, 3rd and 4th line biologics were anti-TNF (25/26), vedolizumab (4/7), ustekinumab (4/4) and vedolizumab (1/1) respectively. Conclusions Children with VEOIBD who have milder disease and do not require biologic therapy achieved better rates of CFCR at 1 year follow up (83.3% compared to 52.7%) but comparable rates at last follow up (78.1% to 81.6%) to those with moderate to severe disease requiring biologic therapy. Primary and secondary outcomes in VEOIBD patients Funding Agencies None
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".